Clinical and Experimental Rheumatology | |
Effects of rituximab in connective tissue disorders related interstitial lung disease | |
Jose Antonio Gonzalez Nieto1  Paolo Airò1  Vidya Limaye1  Francisco Garcia Hernàndez1  Jerome Avouac1  Silvia Bellando-Randone1  Marco Matucci-Cerinic1  Serena Guiducci1  Yannick Allanore1  Britta Maurer1  Gemma Lepri1  Jelena Blagojevic1  Francisco Anguita Santos1  Valeria Riccieri1  Albert Selva-O'Callaghan1  Oliver Distler1  Suzana Jordan1  | |
关键词: Systemic sclerosis; mixed connective tissue disease; anti-synthetase syndrome; rituximab; lung involvement; therapy; Mixed connective tissue disease; systemic sclerosis; anti-synthetase syndrome; rituximab; lung involvement; therapy; | |
DOI : | |
学科分类:医学(综合) | |
来源: Pacini Editore SpA | |
【 摘 要 】
OBJECTIVES: Interstitial lung disease (ILD) is a key prognostic factor in connective tissue disorders (CTDs). The aim of our study was to assess the changes in pulmonary functional tests (PFTs) in various CTDs, including anti-synthetase syndrome (SYN), systemic sclerosis (SSc) and mixed connective tissue disorder (MCTD), following the use of rituximab therapy. METHODS: A multicentre retrospective analysis of patients with ILD secondary to SYN (n=15), MCTD (n=6) and SSc (n=23). PFTs were performed at baseline and at 1 and 2 years of follow-up. The primary outcome was the change in forced vital capacity (FVC) at 1 year. RESULTS: In the SYN population, median FVC changed from 53.0% (42.0-90.0) at baseline to 51.4% (45.6-85.0) at 1 year and 63.0 (50-88) (p=0.6) at 2 years (p=0.14). In SSc, FVC changed from 81.0% (66.0-104.0) at baseline to 89.0% (65.0-113.0) at 1 year (p=0.1) and 74.5 (50-91) at 2 years (p=0.07). In the MCTD population, FVC changed from 64.5% (63.0-68.0) at baseline to 63.0% (59.0-71.0) at 1 year (p=0.6) and 61 (59-71) after 2 years (p=0.8). DLCO showed a trend for improvement in the SYN population (p=0.06 at 1 year and 0.2 at years) while changes remain non-significant in the SSc and MCTD patients. In SYN patients, the percentage of responders at 1 year for FVC (33.3%) was greater than in SSc (9.5%) (p=0.07) and MCTD (17%) (p=0.45). RTX showed a satisfactory safety profile. CONCLUSIONS: A trend of improvement of PFTs was observed in SYN patients although not reaching significance, while SSc and MCTD patients were stabilised.
【 授权许可】
Unknown
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201912020417695ZK.pdf | 287KB | download |